| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
General Counsel
1 company
John R Moore is General Counsel at EWTX. John R Moore's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $667K at current prices.
Our model assigns John R Moore a below-average insider score of 44/100, based on 28 past trades. Over a 12-month horizon, 28.6% of those trades were profitable, with an average 12-month return of -30.6%.
The EWTX filings lean toward selling, a net 329,776 shares.
John R Moore has 25 Form 4 filings on record from August 2021 to August 2026, all as General Counsel at Edgewise Therapeutics (EWTX), 2021–2026.
The 81 reported transactions were 35 option exercises, 35 open-market sales and 11 option or other derivative awards.
Counted by filing, the open-market trades come to no purchases and 17 sales worth about $4.5M.
The largest open-market sale was 70,922 shares of EWTX at an average $28.15 on September 23, 2024, about $2.0M. Twelve months later EWTX was down 43%.
1 of the 8 sales since April 2023 was made under a Rule 10b5-1 trading plan; the other 7 were not.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 12, 2026 | EWTX Edgewise Therapeutics, Inc. | General Counsel | Sale+OE | 5,016 | $43.82 | $219,822.65 | -22.1% | - | - | |
| Aug 12, 2025 | EWTX Edgewise Therapeutics, Inc. | General Counsel | Sale+OE | 2,098 | $13.39 | $28,097.26 | -17.0% | +36.5% | +225.3% | |
| May 2, 2025 | EWTX Edgewise Therapeutics, Inc. | General Counsel | Sale+OE | 1,930 | $16.45 | $31,756.61 | -22.8% | -15.7% | +81.0% | |
| Sep 23, 2024 | EWTX Edgewise Therapeutics, Inc. | General Counsel | Sale+OE | 70,922 | $28.15 | $1,996,574.40 | -95.6% | +13.2% | -43.0% | |
| May 2, 2024 | EWTX Edgewise Therapeutics, Inc. | General Counsel | Sale+OE | 1,956 | $18.91 | $36,987.96 | -37.6% | -11.7% | -12.3% | |
| Feb 9, 2024 | EWTX Edgewise Therapeutics, Inc. | General Counsel | Sale+OE10b5-1 | 29,835 | $20.00 | $596,805.46 | - | +2.7% | +35.4% | |
| Dec 27, 2023 | EWTX Edgewise Therapeutics, Inc. | General Counsel | Sell | 8,497 | $10.50 | $89,218.50 | -100% | +41.7% | +145.1% | |
| May 2, 2023 | EWTX Edgewise Therapeutics, Inc. | General Counsel | Sale+OE | 1,897 | $8.90 | $16,892.60 | -22.4% | -16.7% | +117.3% | |
| Oct 3, 2022 | EWTX Edgewise Therapeutics, Inc. | General Counsel | Sale+OE | 4,730 | $9.76 | $46,154.87 | -61.2% | -9.6% | -40.1% | |
| Sep 6, 2022 | EWTX Edgewise Therapeutics, Inc. | General Counsel | Sale+OE | 4,730 | $10.91 | $51,597.72 | -61.2% | -15.8% | -38.1% |